Bayer Considers Divesting Dermatology Biz

Sep 08, 2016

Reuters

Bayer AG is considering selling its dermatology business to push forward its deal with Monsanto Co., Bloomberg reported, citing sources. Bayer is working with JPMorgan Chase & Co. on the sale, which could be worth more than $1.12 billion.

The article noted the dermatology business could attract interest from existing makers of skincare products including Nestle SA's Galderma, Allergan Plc and Almirall SA, as well as private equity firms.

Read the Reuters story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments